Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Merck Kgaa Dm 5 (MKGAF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTHER OTC]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTHER OTC]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 13,337,568
  • Shares Outstanding, K 129,240
  • Annual Sales, $ 16,626 M
  • Annual Income, $ 1,803 M
  • 36-Month Beta 0.68
  • Price/Sales 0.79
  • Price/Cash Flow 2.63
  • Price/Book 0.82
  • Price/Earnings ttm 14.96
  • Earnings Per Share ttm 3.46
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 02/27/18
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
99.7000 +3.51%
on 02/09/18
112.0200 -7.87%
on 01/23/18
-9.0000 (-8.02%)
since 01/16/18
3-Month
99.7000 +3.51%
on 02/09/18
112.2000 -8.02%
on 01/16/18
-3.0400 (-2.86%)
since 11/16/17
52-Week
99.7000 +3.51%
on 02/09/18
124.4000 -17.04%
on 05/12/17
-6.1900 (-5.66%)
since 02/16/17

Most Recent Stories

More News
Vertex (VRTX) Q4 Earnings Beat on Strong CF Products Sales

Vertex Pharma (VRTX) fourth-quarter earnings increase from the year-ago period led by strong sales of CF drugs and lower operating expenses.

CNCE : 21.20 (-0.98%)
JNJ : 130.36 (+0.35%)
VRTX : 157.59 (-0.19%)
MKGAF : 103.2000 (-0.47%)
Roche MS Drug Ocrevus Gets Marketing Authorization in Europe

Roche's (RHHBY) multiple sclerosis drug Ocrevus gets approval in Europe thereby boosting its neuroscience portfolio. The drug is already approved in the United States.

EXEL : 29.47 (+1.27%)
RHHBY : 29.8500 (+0.78%)
MKGAF : 103.2000 (-0.47%)
BIIB : 287.91 (+1.09%)
What's Happening in Advanced Renal Cell Carcinoma Space?

The advanced renal cell carcinoma space is back in focus as the FDA approved Cabometyx for treatment-naive patients. Investors will keep an eye on other combination therapies being evaluated for the treatment...

MRK : 54.85 (+0.51%)
NVS : 84.80 (-0.47%)
EXEL : 29.47 (+1.27%)
RHHBY : 29.8500 (+0.78%)
PFE : 36.06 (+0.90%)
MKGAF : 103.2000 (-0.47%)
BMY : 65.94 (-0.89%)
Pfizer/Merck KGaA's Bavencio Fails in Gastric Cancer Study

Pfizer & Merck KGaA's (MKGAF) Bavencio/avelumab fails in a phase III study evaluating it for the treatment of gastric cancer in the third-line setting.

JNJ : 130.36 (+0.35%)
HLUYY : 53.3880 (-1.43%)
PFE : 36.06 (+0.90%)
MKGAF : 103.2000 (-0.47%)
Orexigen (OREX) Q3 Loss Narrower Than Expected, Stock Up

Orexigen (OREX) reported a narrower-than-expected loss on higher Contrave volumes.

OREX : 1.37 (+9.60%)
SCMP : 18.05 (+0.28%)
TEVA : 20.03 (+1.16%)
MKGAF : 103.2000 (-0.47%)
Merck KGaA (MKGAF) Q3 Earnings Decline Y/Y, Revenues Flat

Merck KGaA (MKGAF) reported dismal third-quarter results with earnings declining year over year. Revenues were flat amid continued negative currency movement.

RHHBY : 29.8500 (+0.78%)
PFE : 36.06 (+0.90%)
MKGAF : 103.2000 (-0.47%)
BMY : 65.94 (-0.89%)
Merck KGaA (MKGAF) Q3 Earnings Down Y/Y, Sales Flat

Merck KGaA (MKGAF) reports a challenging third-quarter with earnings down year-over-year and sales remaining flat.

MKGAF : 103.2000 (-0.47%)
What's in the Cards for Merck KGaA (MKGAF) in Q3 Earnings?

Merck's (MKGAF) Healthcare and Life Science segments are expected to drive third-quarter sales. The company is progressing with its oncology drug, Bavencio and is also focusing on streamlining its business....

INO : 4.18 (-0.95%)
PFE : 36.06 (+0.90%)
MKGAF : 103.2000 (-0.47%)
PIRS : 8.19 (+0.86%)
Biogen & 6 Other Multiple Sclerosis Drug Stocks in Focus: Here's Why

Late last week, Biogen (BIIB) and six other pharma and biotech stocks were in the news due to the pricing of their multiple sclerosis ("MS") drugs.

BAYRY : 30.1800 (+0.23%)
NVS : 84.80 (-0.47%)
TEVA : 20.03 (+1.16%)
RHHBY : 29.8500 (+0.78%)
MKGAF : 103.2000 (-0.47%)
SNY : 39.74 (-0.28%)
BIIB : 287.91 (+1.09%)
Merck KGaA (MKGAF) Q2 Earnings Up Y/Y

Merck KGaA (MKGAF) reports second-quarter results with earnings rising year-over-year and sales registering organic growth.

MKGAF : 103.2000 (-0.47%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Key Turning Points

2nd Resistance Point 103.2000
1st Resistance Point 103.2000
Last Price 103.2000
1st Support Level 103.2000
2nd Support Level 103.2000

See More

52-Week High 124.4000
Fibonacci 61.8% 114.9646
Fibonacci 50% 112.0500
Fibonacci 38.2% 109.1354
Last Price 103.2000
52-Week Low 99.7000

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.